Biotech | May 10, 2022
Bora Pharmaceuticals acquires Eden Biologics CDMO assets
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Subscribe To Our Newsletter & Stay Updated
